| Pharmaceutical and Biotechnology companies are adopting Personalized medicine. |
|
Most CEO’s from pharma companies deliver the message that compounds will not be taken into the clinic without a set of biomarkers. As a consequence of this new translational research, groups have been started within the pharmaceutical companies and substantial investments are being made into discovery and development of biomarkers. However, the reorganization within the healthcare industry will still need considerable time and effort. Particularly on the clinical development side, many changes are needed. To mention a few:
• Adoption of new adaptive clinical trial designs to allow for the optimal use of biomarkers during the trial • Regulatory approval of medicine with companion test combinations • New insurance coverage and reimbursement strategies sufficiently valuing Personalized medicine. |